Disease progression, treatments, hospitalization, and clinical outcomes in acute GVHD: a multicenter chart review

• Published in: Bone marrow transplantation (Basingstoke) Vol. 57; no. 10; pp. 1581 - 1585
• Main Authors: Holtan, Shernan G., Yu, Jingbo, Choe, Hannah K., Paranagama, Dilan, Tang, Jackson, Naim, Ahmad, Galvin, John, Joachim Deeg, H.
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 01-10-2022; Nature Publishing Group
• Subjects: 631/250/1904; 692/699/249/1529; Bone marrow; Cell Biology; Clinical outcomes; Corticoids; Corticosteroids; Diagnosis; Graft versus host disease; Graft-versus-host reaction; Health services; Hematology; Internal Medicine; Medicine; Medicine & Public Health; Mortality; Patients; Public Health; Stem cell transplantation; Stem Cells; Transplantation
• ISSN: 0268-3369; 1476-5365
• DOI: 10.1038/s41409-022-01764-w

Acute graft-versus-host disease (GVHD) remains a barrier to successful allogeneic hematopoietic cell transplantation (HCT) outcomes. This multicenter, retrospective chart review describes disease progression, treatment patterns, hospitalizations, and clinical outcomes among 475 patients (≥12 years old) who developed grades II–IV acute GVHD after their first HCT (January 2014–June 2016). Median (interquartile range) age at HCT was 55 (44–63) years. From the date of acute GVHD diagnosis, 190 patients (40.0%) experienced progression to more severe disease and/or developed new organ involvement. Among 431 patients with grades II–IV acute GVHD at diagnosis, 73.1% received first-line systemic corticosteroids. During follow-up (median 524 days since acute GVHD diagnosis), 23.4% of patients had an increase in steroid dose and 44.4% were unable to taper below 10 mg/day. Over half of patients (54.9%) required ≥1 hospital readmission within 100 days post-HCT (≥2 readmissions in 22.3%); mean inpatient length of stay upon readmission was 27.5 days. Approximately half of patients (52.8%) died during follow-up; 1-year overall mortality from date of acute GVHD diagnosis and nonrelapse mortality rates were 35.2% and 25.5%, respectively. Overall, patients who developed acute GVHD following HCT had poor clinical outcomes, highlighting the unmet need for early and effective treatment strategies.